

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 15 janvier 2026 10:23

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Enzootic bovine leukosis
*Address of laboratory:	Al. Partyzantow str. 57 24-100 Pulawy
*Tel:	+48-81 889.31.14
*E-mail address:	jkuzmak@piwet.pulawy.pl
Website:	https://www.piwet.pulawy.pl
*Name (including Title) of Head of Laboratory (Responsible Official):	Marcin Smreczak, DVM, PhD, ScD
*Name (including Title and Position) of WOAH Reference Expert:	Jacek Kuźmak, DVM, PhD, Professor
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
ELISA (blocking and screening format)	Yes	1605	0
Agar Gel Immunodiffusion Test (AGID)	Yes	31	0
Direct diagnostic tests			
PCR (nested and real time)	Yes	10	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

Jacek Kuzmak - - POLAND

7. Did your laboratory validate diagnostic methods according to WOAHS Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHS Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHS Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHS Member?

Yes

Name of the WOAHS Member Country receiving a technical consultancy	Purpose	How the advice was provided
KAZAKHSTAN	Query regarding verification of documentation concerning the nomination of the WOAHS reference laboratory for EBL	by e-mail
THAILAND	Question about preparing documentation for the WOAHS twinning project in cooperation with NIAH	by e-mail
UKRAINE	Query regarding validation of ELISA kit for detection of BLV antibodies in milk samples	by e-mail
UKRAINE	Query regarding participation in PT	by e-mail
SLOVAKIA	Query regarding participation in PT	by e-mail
BOSNIA AND HERZEGOVINA	Query regarding participation in PT	by e-mail
FRANCE	Question about the possibility of testing for the presence of BLV in calf serum preparations	by e-mail
JAPAN	Question about legislation related to the status of EBL-free cattle herds	by e-mail

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHS Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHS Member Countries involved other than your country
Co-infection with bovine retroviruses (BLV, BFV, BIV) in dairy cattle from Pakistan	4 months	Estimation of seroprevalence of infection with bovine retroviruses and analysis of possible impact of BIV and BFV on infection with BLV	Animal Quarantine Department, Peshawar, Pakistan	PAKISTAN

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHS?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

National surveillance data which confirms official freedom from EBL

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

2

Anna Ryło, Marzena Rola-Łuszczak, Jacek Michał Kuźmak. Distribution of proviral DNA of bovine leukaemia virus in blood and different tissues in asymptotically infected cattle. J Vet Res 69, 2025 DOI:10.2478/jvetres-2025-0063

Pluta A, Droscha C. Identification of novel RNA polymerase III promoters in bovine leukemia virus miRNA cluster by cross-taxa analysis of small non-coding RNAs. BMC Genomics. 2025 Oct 6;26(1):882. doi: 10.1186/s12864-025-12074-y.

b) International conferences:

2

Marzena Rola-Łuszczak, Anna Ryło, Ewelina Iwan, Arkadiusz Bomba i Jacek Kuźmak. Molecular analysis of bovine leukaemia virus isolates emerging in Poland in the years 2021-2024; 13th International Congress for Veterinary Virology, Słowenia, Portoroz, 2-5 September, 2025.

Aneta Pluta. 8th Annual training course on Viral Bioinformatics and Genomics. MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Rd, Glasgow, G61 1QH, Szkocja. Glasgow 16-20. June, 2025.

c) National conferences:

1

Jacek Kuźmak. Current topics related to BLV infection in Poland. Lecture for veterimary inspectors, Pulawy, WCKP, 05.03.2025..

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
PN-ENIOS/IEC 17025:2018-2 PN-ENIOS/IEC 17025:2018-2	pdf	AB 1016_wyd. 25.pdf

19. Is your quality management system accredited?

Jacek Kuzmak - - POLAND

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA, Agar Gel Immunodiffusion Test, PCR	PCA (Polish Accreditation Center) which is a part of ALAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

NVRI maintains functioning laboratory biological risk management system, which ensure that the laboratory is in compliance with applicable local, national and international standards and requirements for biosafety and laboratory biosecurity.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS
Updating of WOAHP Manual, chapter related do EBL	Exchange of information included in WOAHP manual	2	WOAHP Reference Laboratory for EBL at APHA, Weybridge, UK
Preparation of a draft WOAHP twinning project: Enzootic Bovine Leukosis: WOAHP Laboratory Twinning Program between Poland and Thailand with the collaboration of the United Kingdom between NVRI, APHA and NIAH in Bangkok, Thailand	Coordination of project's preparation	2	WOAHP Reference Laboratory for EBL at APHA, Weybridge, UK

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen during the past 2 years?

No

The laboratory did not organize or participate in PT with other WOAHP Reference Laboratories for EBL

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAHP Member Countries
Detection of BLV antibody in serum samples by ELISA and	Organizer and provider of serum samples	21	ELISA, AGID	BOSNIA AND HERZEGOVINA, CROATIA, ESTONIA, FINLAND, FRANCE, GERMANY, GREECE, HUNGARY, KAZAKHSTAN, LATVIA, LITHUANIA,

AGID tests

MOLDOVA, SLOVAKIA, SPAIN, TURKEY, UKRAINE,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?H?

Yes

Kind of consultancy	Location	Subject (facultative)
Review and update of the WOA?H Terrestrial Manual Chapter for EBL	on line	EBL
The head of the EBL Reference Laboratory participated (November 2024 - December 2025) as an expert in the working group 'Leukose bovine enzootique à la Réunion - LBE La Réunion' established by ANSES to develop a strategy for control of EBL on Réunion Island.	on line/ANSES headquarters	EBL

29. Additional comments regarding your report:

Yes

Q4/5 and 8/9: Not applicable: bovine leukemia virus is a retrovirus, and at th emoment no vaccine was developed to this pathogen.

Q6 and 7: The diagnostic techniques are established so whilst their performance is continuously monitored limited updates have been required

Q15: answer "No", as explained in Q14 surveillance was conducted, as BLV was not detected there was accordingly no need for follow up.